Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
COVID-19
FDA grants EUA for Lucira Health’s COVID-19 and flu combination test
Lucira Health has received FDA emergency use authorization (EUA) for its test to detect and differentiate COVID-19 and both strains of influenza.
November 23, 2022
Meridian Bioscience Q4 revenues drop 14% on lower COVID-19 testing, misses analysts' estimates
Diagnostics segment revenue growth was driven by nonmolecular assay products, which increased 22%.
November 22, 2022
Sense Biodetection inks deal for distribution of COVID-19 testing platform in the Netherlands, Belgium, Luxembourg
Sense Biodetection has signed a distribution deal with R-Biopharm Nederland, bringing its instrument-free platform for COVID-19 testing to the Benelux Union.
November 22, 2022
NIH website enables anonymous reporting of at-home COVID-19 test results
COVID-19 test results provide valuable data that public health departments can use to assess the needs and modify the responses in the local community, the state, or the nation, NIH noted.
November 22, 2022
Genabio Diagnostics COVID-19 self-test available on Amazon
2San, a London-based medical devices distributor of the test, said that according to clinical data the device can identify whether an individual has been infected by any existing SARS-CoV-2 variant, with 91.89% sensitivity and 100% specificity.
November 21, 2022
Lucira Health launches online COVID-19 test-to-treat program, partners with Pfizer
Users of Lucira Health's at-home molecular COVID-19 test can capture results via a smartphone and obtain a prescription through a consultation with a physician.
November 17, 2022
Most Popular
DNA forensic evidence frees Ohio man of rape, attempted rape
Low-value prostate cancer screening has Medicare spending ramifications, study finds
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
PerkinElmer launches adeno-associated virus vector detection kits for research
Widespread HbA1c screening enables earlier type 2 diabetes diagnosis in U.K. study
Pictor, Rako Science, Tasso providing COVID-19 antibody testing in New Zealand
The assay, using a remote collection device from Tasso, detects whether the patient has spike protein and nucleocapsid protein antibodies or spike protein antibodies alone, which would indicate vaccination.
November 17, 2022
Long COVID patients at risk, whether hospitalized or not
Spanish researchers reported that the percentage of patients with at least one post–COVID-19 symptom two years after acute infection was 59.7% for hospitalized patients, while the percentage of those who had not required hospitalization was 67.5%.
November 16, 2022
Virusight, Technogenetics developing 20-second COVID-19 diagnostic test
Earlier this year, the firms launched a CE-marked COVID-19 test that uses AI and a portable spectrophotometer.
November 16, 2022
OIG report outlines testing decline for numerous medical conditions during pandemic
The number of beneficiaries with some chronic medical conditions that are common among Medicare beneficiaries, such as type 2 diabetes, kidney disease, and heart disease, dropped by a larger percentage than the average drop for all tests.
November 14, 2022
Study calls attention to disparities in COVID-19 test and treatment access
Researchers examined disparities in access to COVID-19 antiviral treatments for minority and high-risk populations, especially those in rural areas.
November 10, 2022
Sense, Bio Nuclear Diagnostics ink Canada distribution agreement for POC COVID-19 MDx test
Sense Biodetection and Bio Nuclear Diagnostics have signed a nonexclusive distribution agreement, which will bring Sense’s Veros COVID-19 testing platform to Canadian markets.
November 10, 2022
Page 1 of 24
Next Page
